Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTRC | Q99895 | 3/20 | 0.40 |
| ▸ | PTPRC | P08575 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | MAOB | P27338 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.34 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25372606 | 0.78 | LMNA (0.44) | CTRCPTPRCKDM4EMAOBALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL27829594 | 0.76 | LMNA (0.43) | CTRCPTPRCKDM4EMAOBALDH1A1 | |
| SCHEMBL28190794 | 0.76 | KDM4E (0.48) | CTRCPTPRCKDM4EMAOBALDH1A1 | |
| SCHEMBL23925707 | 0.76 | HDAC4 (0.53) | CTRCPTPRCKDM4EMAOBALDH1A1 | |
| SCHEMBL812897 | 0.72 | CTRC (0.48) | CTRCKDM4EMAOBALDH1A1RAB9A | |
| SCHEMBL7965216 | 0.72 | CTRC (0.37) | CTRCPTPRCKDM4EMAOBALDH1A1 | |
| SCHEMBL346072 | 0.71 | MAOB (0.41) | CTRCKDM4EMAOBALDH1A1RAB9A | |
| SCHEMBL25706171 | 0.69 | CHRM2 (0.51) | CTRCPTPRCALDH1A1CHRM2CHRM4 | |
| SCHEMBL25567561 | 0.68 | ALOX15 (0.46) | CTRCKDM4EALDH1A1RAB9ACA9 | |
| Naphthalene SCHEMBL29025700 | 0.68 | KDM4E (0.46) | CTRCKDM4EMAOBALDH1A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288537-B2 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-10-16 | — | — | US | disclosed |
| US-20120077830-A1 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-29 | — | — | US | disclosed |
| US-8093392-B2 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-01-10 | — | — | US | disclosed |
| US-20110130436-A1 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-06-02 | — | — | US | disclosed |
| EP-2308845-A2 | Caspase inhibitors and uses thereof | Vertex Pharmceuticals Incorporated (US) | 2011-04-13 | — | — | EP | disclosed |
| EP-2308844-A2 | Caspase inhibitors and uses thereof | Vertex Pharmceuticals Incorporated (US) | 2011-04-13 | — | — | EP | disclosed |
| EP-2308846-A2 | Caspase inhibitors and uses thereof | Vertex Pharmceuticals Incorporated (US) | 2011-04-13 | — | — | EP | disclosed |
| US-7906650-B2 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-15 | — | — | US | disclosed |
| US-20090131456-A1 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2009-05-21 | — | — | US | disclosed |
| US-7517987-B2 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICAL INCORPORATED (US) | 2009-04-14 | — | — | US | disclosed |
| US-20030232846-A1 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2003-12-18 | — | — | US | disclosed |
| EP-1244626-A2 | CASPASE INHIBITORS AND USES THEREOF | Vertex Pharmaceuticals Incorporated (US) | 2002-10-02 | — | — | EP | disclosed |
| WO-2001042216-A2 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2001-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131456-A1 | CASPASE INHIBITORS AND USES THEREOF | CASP1, CASP3, CASP2 | CTRC 202/4885PTPRC 3896/4885KDM4E 2131/4885 |
| US-20120077830-A1 | CASPASE INHIBITORS AND USES THEREOF | CASP1, CASP3, CASP2 | CTRC 202/4885PTPRC 3896/4885KDM4E 2131/4885 |
| US-20110130436-A1 | CASPASE INHIBITORS AND USES THEREOF | CASP1, CASP3, CASP2 | CTRC 202/4885PTPRC 3896/4885KDM4E 2131/4885 |
| US-20030232846-A1 | Caspase inhibitors and uses thereof | CASP1, CASP3, CASP2 | CTRC 215/4885PTPRC 3876/4885KDM4E 2305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.